Can an epigenetic pill boost a cancer radiation treatment?
NCT ID NCT05178693
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a drug called ASTX727 can help a radiation therapy called Lutathera work better for people with metastatic neuroendocrine tumors. The idea is that ASTX727 may turn back on a receptor on tumor cells that Lutathera needs to target. About 27 participants will take ASTX727 for five days before receiving Lutathera, and researchers will use special scans to see if the receptor reappears.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (cedazuridine and decitabine) and Lutathera (lutetium Lu 177 dotatate)
What this could lead to
If it works, this could make Lutathera more effective for more patients with neuroendocrine tumors by reactivating a key receptor.
What could go wrong
This is a very early Phase 1 trial with only 27 people, so it may not show clear benefit. The combination could also cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hammersmith Hospital
RECRUITINGLondon, London, City of, W12 0HS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••